Minimizing risk while maximizing opportunity: The infectious disease organ offer process survey.
donor calls
infectious disease
organ evaluation
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
22 Jul 2024
22 Jul 2024
Historique:
received:
04
06
2024
accepted:
30
06
2024
medline:
22
7
2024
pubmed:
22
7
2024
entrez:
22
7
2024
Statut:
aheadofprint
Résumé
The purpose of this study was to understand how transplant infectious disease (TID) physicians assess a potential donor with known or suspected infection and describe posttransplant management. We designed a survey of 10 organ offer scenarios and asked questions pertaining to organ acceptability for transplantation and management posttransplant. The survey was distributed to TID clinicians via transplant society listservs and email. Responses were recorded in REDCap, and descriptive statistics were employed. One hundred thirteen infectious disease physicians responded to the survey, of whom 85 completed all cases. Respondents were generally in agreement regarding organ acceptability, although some divergence was seen when evaluating lungs from donors with influenza, tuberculosis, or multidrug-resistant Acinetobacter infection. Posttransplant management showed more variation. Areas of optimization were identified: (1) Further understanding of where risk-mitigation strategies within the donor offer process may improve donor acceptability and therefore organ utilization; (2) importance of recipient considerations in assessing degree of infectious risk; and (3) gaps in evidenced-based data regarding optimal posttransplant management of recipients. Evaluation of donor offers by TID clinicians is a complex process. Although the survey does not itself serve to make recommendations regarding best practices, it highlights areas where generation of data to inform acceptance and management practices may allow for improved organ utilization and recipient management.
Sections du résumé
BACKGROUND
BACKGROUND
The purpose of this study was to understand how transplant infectious disease (TID) physicians assess a potential donor with known or suspected infection and describe posttransplant management.
METHODS
METHODS
We designed a survey of 10 organ offer scenarios and asked questions pertaining to organ acceptability for transplantation and management posttransplant. The survey was distributed to TID clinicians via transplant society listservs and email. Responses were recorded in REDCap, and descriptive statistics were employed.
RESULTS
RESULTS
One hundred thirteen infectious disease physicians responded to the survey, of whom 85 completed all cases. Respondents were generally in agreement regarding organ acceptability, although some divergence was seen when evaluating lungs from donors with influenza, tuberculosis, or multidrug-resistant Acinetobacter infection. Posttransplant management showed more variation. Areas of optimization were identified: (1) Further understanding of where risk-mitigation strategies within the donor offer process may improve donor acceptability and therefore organ utilization; (2) importance of recipient considerations in assessing degree of infectious risk; and (3) gaps in evidenced-based data regarding optimal posttransplant management of recipients.
CONCLUSION
CONCLUSIONS
Evaluation of donor offers by TID clinicians is a complex process. Although the survey does not itself serve to make recommendations regarding best practices, it highlights areas where generation of data to inform acceptance and management practices may allow for improved organ utilization and recipient management.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14342Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Woolley AE, Singh SK, Goldberg HJ, et al. Heart and lung transplants from HCV‐infected donors to uninfected recipients. N Engl J Med. 2019;380(17):1606‐1617. https://doi.org/10.1056/nejmoa1812406
Reese PP, Abt PL, Blumberg EA, et al. Twelve‐month outcomes after transplant of hepatitis C–infected kidneys into uninfected recipients a single‐group trial. Ann Intern Med. 2018;169(5):273‐281. https://doi.org/10.7326/M18‐0749
Kwong AJ, Wall A, Melcher M, et al. Liver transplantation for hepatitis C virus (HCV) non‐viremic recipients with HCV viremic donors. Am J Transplant. 2019;19(5):1380‐1387. https://doi.org/10.1111/ajt.15162
Bethea ED, Gaj K, Gustafson JL, et al. Pre‐emptive pangenotypic direct acting antiviral therapy in donor HCV‐positive to recipient HCV‐negative heart transplantation: an open‐label study. Lancet Gastroenterol Hepatol. 2019;4(10):771‐780. https://doi.org/10.1016/S2468‐1253(19)30240‐7
Kapila N, Menon KVN, Al‐Khalloufi K, et al. Hepatitis C virus NAT‐positive solid organ allografts transplanted into hepatitis C virus–negative recipients: a real‐world experience. Hepatology. 2020;72(1):32‐41. https://doi.org/10.1002/hep.31011
Reese PP, Abt PL, Blumberg EA, Goldberg DS. Transplanting hepatitis C–positive kidneys. N Engl J Med. 2015;373(4):303‐305. https://doi.org/10.1056/nejmp1505074
Lentine KL, Smith JM, Miller JM, et al. OPTN/SRTR 2021 annual data report: kidney. Am J Transplant. 2023;23(2S1):S21‐S120. https://doi.org/10.1016/j.ajt.2023.02.004
Boxer B. S.330—113th Congress (2013‐2014): HIV Organ Policy Equity Act. 2013. Accessed February 25, 2019. https://www.congress.gov/bill/113th‐congress/senate‐bill/330
Durand CM, Zhang W, Brown DM, et al. A prospective multicenter pilot study of HIV‐positive deceased donor to HIV‐positive recipient kidney transplantation: HOPE in action. Am J Transplant. 2021;21(5):1754‐1764. https://doi.org/10.1111/ajt.16205
Goldman JD, Pouch SM, Woolley AE, et al. Transplant of organs from donors with positive SARS‐CoV‐2 nucleic acid testing: a report from the organ procurement and transplantation network Ad Hoc Disease Transmission Advisory Committee. Transpl Infect Dis. 2023;25(1):1‐11. https://doi.org/10.1111/tid.14013
Kaul DR, Vece G, Blumberg E, et al. Ten years of donor‐derived disease: a report of the Disease Transmission Advisory Committee. Am J Transplant. 2021;21(2):689‐702. https://doi.org/10.1111/ajt.16178
Fernández García OA, Singh AE, Gratrix J, Smyczek P, Doucette K. Serologic follow‐up of solid organ transplant recipients who received organs from donors with reactive syphilis tests: a retrospective cohort study. Clin Transplant. 2023;37(2):e14896. https://doi.org/10.1111/ctr.14896
Delmonico FL, Snydman DR. Organ donor screening for infectious diseases: review of practice and implications for transplantation. Transplantation. 1998;65(5):603‐610. https://doi.org/10.1097/00007890‐199803150‐00001
Screening of donor and recipient prior to solid organ transplantation. Am J Transplant. 2004;4(10 suppl):10‐20. https://doi.org/10.1111/j.1600‐6135.2004.00616.x
Marek A, Inkster T. A syphilis‐positive organ donor‐management of the cardiac transplant recipient: a case report and review of the literature. Sex Transm Dis. 2012;39(6):485‐486. https://doi.org/10.1097/OLQ.0b013e318249db35
Gibel LJ, Sterling W, Hoy W, Harford A. Is serological evidence of infection with syphilis a contraindication to kidney donation? Case report and review of the literature. J Urol. 1987;138(5):1226‐1227. https://doi.org/10.1016/S0022‐5347(17)43558‐0
Len O, Garzoni C, Lumbreras C, et al. Recommendations for screening of donor and recipient prior to solid organ transplantation and to minimize transmission of donor‐derived infections. Clin Microbiol Infect. 2014;20(s7):10‐18. https://doi.org/10.1111/1469‐0691.12557
Malinis M, Boucher HW. Screening of donor and candidate prior to solid organ transplantation—Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13548. https://doi.org/10.1111/ctr.13548
Ison MG, Grossi P. Donor‐derived infections in solid organ transplantation. Am J Transplant. 2013;13(suppl 4):22‐30. https://doi.org/10.1111/ajt.12095
Ison MG, Nalesnik MA. An update on donor‐derived disease transmission in organ transplantation. Am J Transplant. 2011;11(6):1123‐1130. https://doi.org/10.1111/j.1600‐6143.2011.03493.x
Lumbreras C, Sanz F, González A, et al. Clinical significance of donor‐unrecognized bacteremia in the outcome of solid‐organ transplant recipients. Clin Infect Dis. 2001;33(5):722‐726. https://doi.org/10.1086/322599
Singh N. Impact of donor bacteremia on outcome in organ transplant recipients. Liver Transpl. 2002;8(10):975‐976. https://doi.org/10.1053/jlts.2002.0080975
Coll P, Montserrat I, Ballester M, et al. Epidemiologic evidence of transmission of donor‐related bacterial infection through a transplanted heart. J Hear Lung Transplant. 1997;16(4):464‐467. http://www.ncbi.nlm.nih.gov/pubmed/9154959
Doucette KE, Al‐Saif M, Kneteman N, et al. Donor‐derived bacteremia in liver transplant recipients despite antibiotic prophylaxis. Am J Transplant. 2013;13(4):1080‐1083. https://doi.org/10.1111/ajt.12133
Johnston L, Chui L, Chang N, et al. Cross‐Canada spread of methicillin‐resistant Staphylococcus aureus via transplant organs. Clin Infect Dis. 1999;29(4):819‐823. https://doi.org/10.1086/520442
Altman DR, Sebra R, Hand J, et al. Transmission of methicillin‐resistant Staphylococcus aureus via deceased donor liver transplantation confirmed by whole genome sequencing. Am J Transplant. 2014;14(11):2640‐2644. https://doi.org/10.1111/ajt.12897
Wolfe CR, Ison MG. Donor‐derived infections: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13547. https://doi.org/10.1111/ctr.13547
Snydman D, Fishman JA, Greenwald MA, Grossi PA. Transmission of infection with human allografts: essential considerations in donor screening. Clin Infect Dis. 2012;55(5):720‐727. https://doi.org/10.1093/cid/cis519
Min EK, Yim SH, Choi MC, et al. Incidence, mortality, and risk factors associated with carbapenem‐resistant Acinetobacter baumannii bacteremia within 30 days after liver transplantation. Clin Transplant. 2023;37(5):e14956. https://doi.org/10.1111/ctr.14956
Freire MP, Pierrotti LC, Oshiro ICVS, et al. Carbapenem‐resistant Acinetobacter baumannii acquired before liver transplantation: impact on recipient outcomes. Liver Transplant. 2016;22(5):615‐626. https://doi.org/10.1002/lt.24389
Aguado JM, Silva JT, Fernández‐Ruiz M, et al. Management of multidrug resistant Gram‐negative bacilli infections in solid organ transplant recipients: SET/GESITRA‐SEIMC/REIPI recommendations. Transplant Rev. 2018;32(1):36‐57. https://doi.org/10.1016/j.trre.2017.07.001
Fischer SA, Lu K. Screening of donor and recipient in solid organ transplantation. Am J Transplant. 2013;13(suppl 4):9‐21. https://doi.org/10.1111/ajt.12094
Goldman JD, Julian K. Urinary tract infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13507. https://doi.org/10.1111/ctr.13507
Sifri CD, Ison MG. Highly resistant bacteria and donor‐derived infections: treading in uncharted territory. Transpl Infect Dis. 2012;14(3):223‐228. https://doi.org/10.1111/j.1399‐3062.2012.00752.x
Bishara J, Goldberg E, Lev S, Singer P, Ashkenazi T, Cohen J. The utilization of solid organs for transplantation in the setting of infection with multidrug‐resistant organisms: an expert opinion. Clin Transplant. 2012;26(6):811‐815. https://doi.org/10.1111/j.1399‐0012.2012.01693.x
Likos AM, Kelvin DJ, Cameron CM, Rowe T, Kuehnert MJ, Norris PJ. Influenza viremia and the potential for blood‐borne transmission. Transfusion. 2007;47(6):1080‐1088. https://doi.org/10.1111/j.1537‐2995.2007.01264.x
Sobata R, Matsumoto C, Igarashi M, et al. No viremia of pandemic (H1N1) 2009 was demonstrated in blood donors who had donated blood during the probable incubation period. Transfusion. 2011;51(9):1949‐1956. https://doi.org/10.1111/j.1537‐2995.2011.03109.x
Matsumoto C, Sobata R, Uchida S, et al. Risk for transmission of pandemic (H1N1) 2009 virus by blood transfusion. Emerg Infect Dis. 2010;16(4):722‐723. https://doi.org/10.3201/eid1604.091795
Stramer SL, Collins C, Nugent T, et al. Sensitive detection assays for influenza RNA do not reveal viremia in US blood donors. J Infect Dis. 2012;205(6):886‐894. https://doi.org/10.1093/infdis/jir863
Hourfar MK, Themann A, Eickmann M, et al. Blood screening for influenza. Emerg Infect Dis. 2007;13(7):1081‐1083. https://doi.org/10.3201/eid1307.060861
Saá P, Fink R V, Dawar H, et al. Prevalence of SARS‐CoV‐2 viremia in presymptomatic blood donors in the delta and omicron variant eras. Open Forum Infect Dis. 2023;10(5):ofad253. https://doi.org/10.1093/ofid/ofad253
Kaul DR, Valesano AL, Petrie JG, et al. Donor to recipient transmission of SARS‐CoV‐2 by lung transplantation despite negative donor upper respiratory tract testing. Am J Transplant. 2021;21(8):2885‐2889. https://doi.org/10.1111/ajt.16532
Le Page AK, Kainer G, Glanville AR, Tu E, Bhonagiri D, Rawlinson WD. Influenza B virus transmission in recipients of kidney and lung transplants from an infected donor. Transplantation. 2010;90(1):99‐102. https://doi.org/10.1097/TP.0b013e3181da1933
Montiel Villalonga P, Martínez‐Alpuente I, Fernández‐Ruiz M, et al. Transplantation of organs from SARS‐CoV‐2‐positive donors: preliminary experience from Spain. Transpl Infect Dis. 2023;25(1):e14008. https://doi.org/10.1111/tid.14008
Ji M, Vinson AJ, Chang SH, et al. Patterns in use and transplant outcomes among adult recipients of kidneys from deceased donors with COVID‐19. JAMA Netw open. 2023;6(5):e2315908. https://doi.org/10.1001/jamanetworkopen.2023.15908
Wang RX, Abu‐Gazala S, Mahmud N. Posttransplant outcomes and trends in use of COVID‐19‐positive deceased donor liver transplantation. Liver Transplant. 2023;29(10):1129‐1133. https://doi.org/10.1097/LVT.0000000000000175
Martini S, Saracco M, Cocchis D, et al. Favorable experience of transplant strategy including liver grafts from COVID‐19 donors: one‐year follow‐up results. Transpl Infect Dis. 2023;25(5):e14126. https://doi.org/10.1111/tid.14126
Ison MG. Influenza prevention and treatment in transplant recipients and immunocompromised hosts. Influenza Other Respir Viruses. 2013;7(suppl 3):60‐66. https://doi.org/10.1111/irv.12170
Kumar D, Morris MI, Kotton CN, et al. Guidance on novel influenza A/H1N1 in solid organ transplant recipients: officially endorsed by the American society of transplantation (AST), the transplantation society (TTS) and the Canadian society of transplantation (CST). Am J Transplant. 2010;10(1):18‐25. https://doi.org/10.1111/j.1600‐6143.2009.02960.x
Kaul DR, Covington S, Taranto S, et al. Solid organ transplant donors with central nervous system infection. Transplantation. 2014;98(6):666‐670. https://doi.org/10.1097/TP.0000000000000117
Pouch SM, Katugaha SB, Shieh WJ, et al. Transmission of eastern equine encephalitis virus from an organ donor to 3 transplant recipients. Clin Infect Dis. 2019;69(3):450‐458. https://doi.org/10.1093/cid/ciy923
Vora NM, Orciari LA, Niezgoda M, et al. Clinical management and humoral immune responses to rabies post‐exposure prophylaxis among three patients who received solid organs from a donor with rabies. Transpl Infect Dis. 2015;17(3):389‐395. https://doi.org/10.1111/tid.12393
Bock MJ, Vaughn GR, Chau P, Berumen JA, Nigro JJ, Ingulli EG. Organ transplantation using COVID‐19‐positive deceased donors. Am J Transplant. 2022;22(9):2203‐2216. https://doi.org/10.1111/ajt.17145
Blair JE. Coccidioidomycosis in liver transplantation. Liver Transplant. 2006;12(1):31‐39. https://doi.org/10.1002/lt.20654
Blair JE, Douglas DD, Mulligan DC. Early results of targeted prophylaxis for coccidioidomycosis in patients undergoing orthotopic liver transplantation within an endemic area. Transpl Infect Dis. 2003;5(1):3‐8. https://doi.org/10.1034/j.1399‐3062.2003.00005.x
Blair JE, Logan JL. Coccidioidomycosis in solid organ transplantation. Clin Infect Dis. 2001;33(9):1536‐1544. https://doi.org/10.1086/323463
Brown J, Benedict K, Park BJ, Thompson GR. Coccidioidomycosis: epidemiology. Clin Epidemiol. 2013;5(1):185‐197. https://doi.org/10.2147/CLEP.S34434
Braddy CM, Heilman RL, Blair JE. Coccidioidomycosis after renal transplantation in an endemic area. Am J Transplant. 2006;6(2):340‐345. https://doi.org/10.1111/j.1600‐6143.2005.01169.x
Miller MB, Hendren R, Gilligan PH. Posttransplantation disseminated coccidioidomycosis acquired from donor lungs. J Clin Microbiol. 2004;42(5):2347‐2349. https://doi.org/10.1128/JCM.42.5.2347‐2349.2004
Tripathy U, Yung GL, Kriett JM, Thistlethwaite PA, Kapelanski DP, Jamieson SW. Donor transfer of pulmonary coccidioidomycosis in lung transplantation. Ann Thorac Surg. 2002;73(1):306‐308. https://doi.org/10.1016/S0003‐4975(01)02723‐0
Wright PW, Pappagianis D, Wilson M, et al. Donor‐related coccidioidomycosis in organ transplant recipients. Clin Infect Dis. 2003;37(9):1265‐1269. https://doi.org/10.1086/378741
Carvalho C, Ferreira I, Gaião S, et al. Cerebral coccidioidomycosis after renal transplantation in a non‐endemic area: case report. Transpl Infect Dis. 2010;12(2):151‐154. https://doi.org/10.1111/j.1399‐3062.2009.00456.x
Brugiére O, Forget E, Biondi G, et al. Coccidioidomycosis in a lung transplant recipient acquired from the donor graft in France. Transplantation. 2009;88(11):1319‐1320. https://doi.org/10.1097/TP.0b013e3181bc22e1
Engelthaler DM, Chiller T, Schupp JA, et al. Next‐generation sequencing of Coccidioides immitis isolated during cluster investigation. Emerg Infect Dis. 2011;17(2):227‐232. https://doi.org/10.3201/eid1702.100620
Blodget E, Jan Geiseler P, Larsen RA, Stapfer M, Qazi Y, Petrovic LM. Donor‐derived Coccidioides immitis fungemia in solid organ transplant recipients. Transpl Infect Dis. 2012;14(3):305‐310. https://doi.org/10.1111/j.1399‐3062.2011.00698.x
Dierberg KL, Marr KA, Subramanian A, et al. Donor‐derived organ transplant transmission of coccidioidomycosis. Transpl Infect Dis. 2012;14(3):300‐304. https://doi.org/10.1111/j.1399‐3062.2011.00696.x
Kusne S, Taranto S, Covington S, et al. Coccidioidomycosis transmission through organ transplantation: a report of the OPTN Ad Hoc Disease Transmission Advisory Committee. Am J Transplant. 2016;16(12):3562‐3567. https://doi.org/10.1111/ajt.13950
Singh N, Huprikar S, Burdette SD, Morris MI, Blair JE, Wheat LJ. Donor‐derived fungal infections in organ transplant recipients: Guidelines of the American Society of Transplantation, Infectious Diseases Community of Practice. Am J Transplant. 2012;12(9):2414‐2428. https://doi.org/10.1111/j.1600‐6143.2012.04100.x
La Hoz RM, Morris MI. Tissue and blood protozoa including toxoplasmosis, Chagas disease, leishmaniasis, Babesia, Acanthamoeba, Balamuthia, and Naegleria in solid organ transplant recipients—Guidelines from the American Society of Transplantation Infectious Diseases Community. Clin Transplant. 2019;33(9):e13546. https://doi.org/10.1111/ctr.13546
Network OPaT. Improve Deceased Donor Evaluation for Endemic Diseases. https://optn.transplant.hrsa.gov/policies‐bylaws/public‐comment/improve‐deceased‐donor‐evaluation‐for‐endemic‐diseases/
La Hoz RM. Transplantation for chagas’ disease: closing the knowledge gap. Curr Opin Infect Dis. 2022;35(5):397‐403. https://doi.org/10.1097/QCO.0000000000000868
Barcan LA, Smud A, Besuschio SA, et al. Quantitative PCR‐based diagnosis and follow‐up of chagas disease primary infection after solid organ transplant: a multicentre study. J Infect Dis. 2023;228(9):1304‐1308. https://doi.org/10.1093/infdis/jiad289
La Hoz RM. Minimizing the risk of donor‐derived events and maximizing organ utilization through education and policy development. Infect Dis Clin North Am. 2023;37(3):443‐458. https://doi.org/10.1016/j.idc.2023.05.002
Malinis M, LaHoz RM, Vece G, et al. Donor‐derived tuberculosis among solid organ transplant recipients in the United States—2008 to 2018. Transpl Infect Dis. 2022;24(2):e13800. https://doi.org/10.1111/tid.13800
Schmidt T, Schub D, Wolf M, et al. Comparative analysis of assays for detection of cell‐mediated immunity toward cytomegalovirus and M. tuberculosis in samples from deceased organ donors. Am J Transplant. 2014;14(9):2159‐2167. https://doi.org/10.1111/ajt.12787
Morris MI, Daly JS, Blumberg E, et al. Diagnosis and management of tuberculosis in transplant donors: a donor‐derived infections consensus conference report. Am J Transplant. 2012;12(9):2288‐2300. https://doi.org/10.1111/j.1600‐6143.2012.04205.x
Geng E, Kreiswirth B, Burzynski J, Schluger NW. Clinical and radiographic correlates of primary and reactivation tuberculosis: a molecular epidemiology study. JAMA. 2005;293(22):2740‐2745. https://doi.org/10.1001/jama.293.22.2740
Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients–Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9). https://doi.org/10.1111/ctr.13512
Shah SZ, Pouch SM, Keller BC, Pope‐Harman A, Tumin D. Outcomes from bacteremic donors in lung transplantation. J Hear Lung Transplant. 2018;37(2):302‐304. https://doi.org/10.1016/j.healun.2017.07.023
Huaman MA, Vilchez V, Mei X, et al. Decreased graft survival in liver transplant recipients of donors with positive blood cultures: a review of the United Network for Organ Sharing dataset. Transpl Int. 2017;30(6):558‐565. https://doi.org/10.1111/tri.12900
Kubak BM, Gregson AL, Pegues DA, et al. Use of hearts transplanted from donors with severe sepsis and infectious deaths. J Hear Lung Transplant. 2009;28(3):260‐265. https://doi.org/10.1016/j.healun.2008.11.911
Vinet L, Zhedanov A. A “missing” family of classical orthogonal polynomials. J Phys A: Math Theor. 2011;44:085201. https://doi.org/10.1088/1751‐8113/44/8/085201
Theodoropoulos NM, Greenwald MA, Chin‐Hong P, Ison MG. Testing deceased organ donors for infections: an organ procurement organization survey. Am J Transplant. 2021;21(5):1924‐1930. https://doi.org/10.1111/ajt.16552
Fishman JA, Greenwald MA, Kuehnert MJ. Enhancing transplant safety: a new era in the microbiologic evaluation of organ donors? Am J Transplant. 2007;7(12):2652‐2654. https://doi.org/10.1111/j.1600‐6143.2007.02023.x
Li AHT, Lam NN, Naylor KL, Garg AX, Knoll GA, Joseph Kim S. Early hospital readmissions after transplantation: burden, causes, and consequences. Transplantation. 2016;100(4):713‐718. https://doi.org/10.1097/TP.0000000000000917
Dharnidharka VR, Stablein DM, Harmon WE. Post‐transplant infections now exceed acute rejection as cause for hospitalization: a report of the NAPRTCS. Am J Transplant. 2004;4(3):384‐389. https://doi.org/10.1111/j.1600‐6143.2004.00350.x
Hamandi B, Husain S, Humar A, Papadimitropoulos EA. Impact of infectious disease consultation on the clinical and economic outcomes of solid organ transplant recipients admitted for infectious complications. Clin Infect Dis. 2014;59(8):1074‐1082. https://doi.org/10.1093/cid/ciu522